Overview

Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.

Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Migraine affects 15% of Western Australians and is a leading cause of suffering and disability in our community (1,2). Research suggests that inflammation of the brain's coverings (meninges) by nerve cell inflammation and the release of 'free radicals', is a cause of migraine. N-acetylcysteine, Vitamin E and Vitamin C are powerful anti-oxidants (free-radical scavengers) that reduce brain inflammation and nerve activity. It is therefore possible these anti-oxidants could reduce the number and severity of migraines. We will study 90 subjects to see if a combination of N-acetylcysteine 600 mg, Vitamin E 250 IU and vitamin C 500 mg (NEC) taken twice daily for 3 months, will reduce migraine attacks. This safe vitamin-based therapy has never been studied and if effective, will play an important role in migraine prevention.
Phase:
Phase 3
Details
Lead Sponsor:
University of Notre Dame Australia
Treatments:
Acetylcysteine
Antioxidants
N-monoacetylcystine